Biomarker Discovery for Nonalcoholic Fatty Liver Disease in Children
儿童非酒精性脂肪肝的生物标志物发现
基本信息
- 批准号:10264938
- 负责人:
- 金额:$ 34.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-16 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAutomobile DrivingBiological AssayBiological MarkersChildChild HealthChildhoodCirrhosisClinicalClinical DataClinical ResearchClinical TrialsCountryDataData AnalysesDatabasesDepositionDevelopmentDiabetes MellitusDiagnosisDiagnosticDietDigestive System DisordersDiseaseEligibility DeterminationExerciseFibrosisFundingGoalsHepatocyteInflammationKidney DiseasesKnowledgeLettersLife StyleLipidsLiver diseasesMachine LearningMeasuresMethodsMissionModelingNational Institute of Diabetes and Digestive and Kidney DiseasesOutcomePathologicPediatric cohortPharmaceutical PreparationsPharmacodynamicsPilot ProjectsPrimary carcinoma of the liver cellsPublishingRandomized Clinical TrialsResearchResearch PersonnelResourcesRiskSamplingSampling StudiesSensitivity and SpecificitySerumSeveritiesSurrogate EndpointTechniquesTechnologyTestingTherapeuticTimeUnited StatesUniversitiesUrologic DiseasesValidationWorkbasebiobankbiomarker discoverybiomarker panelcirculating biomarkersclinical careclinical phenotypecohortdata accessdata reductiondeep learningdesigndiabetes riskdisorder subtypedrug developmentearly detection biomarkersexperienceimaging modalityimprovedlipidomicsliver biopsymembermetabolomicsmultidisciplinarynon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel markerobesity in childrenpediatric non-alcoholic fatty liver diseasepersonalized medicinerepositoryresearch and developmentresponseresponse biomarkerspecific biomarkerssugartherapeutic developmenttool
项目摘要
Project Abstract
Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, the most common
liver disease in children in the United States. The disease affects almost 1/3 of all obese children, estimated to
be approximately 7 million children. Treatment is based on lifestyle changes such as a low sugar diet and
increasing exercise, but no therapeutics are approved for children or adults. Currently, diagnosis of NASH
requires a liver biopsy, which is cumbersome, expensive and has inherent risk. The lack of 1) non-invasive
biomarkers to diagnose NASH and 2) pharmacodynamic/response biomarkers of NASH to therapy are
considered by many to be an important barrier in the field. These biomarkers are needed to advance clinical
care, focusing resources on the children with the most progressive form of the disease. And they are needed to
drive therapeutic development because children with NASH are prioritized for participation in clinical trials and
response biomarkers for NASH are needed to become surrogate endpoint biomarkers for clinical trials to
accelerate drug development. This proposal represents an exceptional multidisciplinary effort to address these
important gaps in knowledge. The project will be led by Dr. Miriam Vos, expert in pediatric NAFLD and
experienced in early biomarker development research. Co-investigators including Dr. Kristal Maner-Smith,
expert in lipidomics and Dr. Ayman Akil, expert in machine learning and biomarker discovery. The team seeks
to develop a panel of biomarkers to predict NASH and to reflect response of NASH to therapy through the 2
following aims. Aim 1 will define and validate a panel of metabolites and lipids diagnostic of NASH in children.
Aim 2 will define and validate a panel of metabolites, lipids and clinical variables that are associated with
treatment induced improvement in NASH. Aims 1 and 2 will both capitalize on the exceptionally high-quality
samples available from the NASH clinical research network and deposited within the NIDDK Central Repository.
Repository serum samples are available from two pediatric clinical studies including the NAFLD Database study
and the TONIC randomized clinical trial and were collected near in time to a liver biopsy as well as with detailed
clinical phenotyping. Validation cohort and control samples will be drawn from the Emory Liver Biopsy
Biorepository study and an ongoing Healthy Control pediatric cohort at Emory. Preliminary data demonstrates
strong associations between specific metabolites and pathologic features of NASH including hepatocyte
ballooning, inflammation and steatosis supporting feasibility. These studies are designed to have a sustained,
powerful impact on the pediatric NASH biomarker field and to directly improve the health of children through
efficient diagnosis of NASH and successful therapeutic development for NASH.
项目摘要
非酒精性脂肪性肝炎 (NASH) 是非酒精性脂肪性肝病的侵袭性形式,是最常见的疾病
美国儿童肝病。该疾病影响了几乎 1/3 的肥胖儿童,估计
大约有700万儿童。治疗基于生活方式的改变,例如低糖饮食和
增加锻炼,但没有批准用于儿童或成人的治疗方法。目前,NASH的诊断
需要进行肝活检,这既麻烦又昂贵,并且具有固有的风险。缺乏1)非侵入性
诊断 NASH 的生物标志物和 2) NASH 对治疗的药效学/反应生物标志物
许多人认为这是该领域的一个重要障碍。需要这些生物标志物来推进临床
护理,将资源集中用于患有病情最严重的儿童。他们需要
推动治疗发展,因为 NASH 儿童优先参与临床试验和
NASH 反应生物标志物需要成为临床试验的替代终点生物标志物
加速药物开发。该提案代表了解决这些问题的特殊多学科努力
知识上的重要差距。该项目将由儿科 NAFLD 专家 Miriam Vos 博士领导
具有早期生物标志物开发研究经验。共同研究人员包括 Kristal Maner-Smith 博士,
脂质组学专家和机器学习和生物标志物发现专家 Ayman Akil 博士。团队寻求
开发一组生物标志物来预测 NASH 并通过 2 来反映 NASH 对治疗的反应
以下目标。目标 1 将定义并验证一组代谢物和脂质诊断儿童 NASH。
目标 2 将定义并验证一组与相关的代谢物、脂质和临床变量
治疗引起 NASH 的改善。目标 1 和 2 都将利用卓越的高质量
样本可从 NASH 临床研究网络获取并存放在 NIDDK 中央存储库中。
储存血清样本可从两项儿科临床研究中获得,包括 NAFLD 数据库研究
和 TONIC 随机临床试验,并在接近肝活检时收集并详细记录
临床表型。验证队列和对照样本将从埃默里大学肝脏活检中抽取
埃默里大学生物样本库研究和正在进行的健康控制儿科队列研究。初步数据表明
特定代谢物与 NASH 病理特征(包括肝细胞)之间的密切关联
气球样变性、炎症和脂肪变性支持可行性。这些研究旨在具有持续的、
对儿科 NASH 生物标志物领域产生强大影响,并通过以下方式直接改善儿童的健康
NASH 的有效诊断和 NASH 治疗的成功开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MIRIAM B. VOS其他文献
MIRIAM B. VOS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MIRIAM B. VOS', 18)}}的其他基金
Sibling Assessment in Prevention of Pediatric NAFLD in Hispanic Children
兄弟姐妹评估在预防西班牙裔儿童儿科 NAFLD 中的作用
- 批准号:
10675355 - 财政年份:2022
- 资助金额:
$ 34.15万 - 项目类别:
Prevention of Pediatric NAFLD in Hispanic Children
西班牙裔儿童 NAFLD 的预防
- 批准号:
10552057 - 财政年份:2021
- 资助金额:
$ 34.15万 - 项目类别:
Prevention of Pediatric NAFLD in Hispanic Children
西班牙裔儿童 NAFLD 的预防
- 批准号:
10383660 - 财政年份:2021
- 资助金额:
$ 34.15万 - 项目类别:
Biomarker Discovery for Nonalcoholic Fatty Liver Disease in Children
儿童非酒精性脂肪肝的生物标志物发现
- 批准号:
10469568 - 财政年份:2020
- 资助金额:
$ 34.15万 - 项目类别:
Biomarker Discovery for Nonalcoholic Fatty Liver Disease in Children
儿童非酒精性脂肪肝的生物标志物发现
- 批准号:
10119937 - 财政年份:2020
- 资助金额:
$ 34.15万 - 项目类别:
Anti-LPS antibody for Pediatric Nonalcoholic Fatty Liver Disease
抗 LPS 抗体治疗小儿非酒精性脂肪肝
- 批准号:
9335406 - 财政年份:2016
- 资助金额:
$ 34.15万 - 项目类别:
Anti-LPS antibody for Pediatric Nonalcoholic Fatty Liver Disease
抗 LPS 抗体治疗小儿非酒精性脂肪肝
- 批准号:
9168600 - 财政年份:2016
- 资助金额:
$ 34.15万 - 项目类别:
National Exposure Assessment Laboratory at Emory
埃默里国家暴露评估实验室
- 批准号:
9062180 - 财政年份:2015
- 资助金额:
$ 34.15万 - 项目类别:
相似国自然基金
成人免疫性血小板减少症(ITP)中血小板因子4(PF4)通过调节CD4+T淋巴细胞糖酵解水平影响Th17/Treg平衡的病理机制研究
- 批准号:82370133
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
依恋相关情景模拟对成人依恋安全感的影响及机制
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
生活方式及遗传背景对成人不同生命阶段寿命及死亡的影响及机制的队列研究
- 批准号:
- 批准年份:2021
- 资助金额:56 万元
- 项目类别:面上项目
成人与儿童结核病发展的综合研究:细菌菌株和周围微生物组的影响
- 批准号:81961138012
- 批准年份:2019
- 资助金额:100 万元
- 项目类别:国际(地区)合作与交流项目
统计学习影响成人汉语二语学习的认知神经机制
- 批准号:31900778
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
- 批准号:
10676358 - 财政年份:2024
- 资助金额:
$ 34.15万 - 项目类别:
A HUMAN IPSC-BASED ORGANOID PLATFORM FOR STUDYING MATERNAL HYPERGLYCEMIA-INDUCED CONGENITAL HEART DEFECTS
基于人体 IPSC 的类器官平台,用于研究母亲高血糖引起的先天性心脏缺陷
- 批准号:
10752276 - 财政年份:2024
- 资助金额:
$ 34.15万 - 项目类别:
Climate Change Effects on Pregnancy via a Traditional Food
气候变化通过传统食物对怀孕的影响
- 批准号:
10822202 - 财政年份:2024
- 资助金额:
$ 34.15万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 34.15万 - 项目类别:
Identifying and testing a tailored strategy to achieve equity in blood pressure control in PACT
确定并测试量身定制的策略,以在 PACT 中实现血压控制的公平性
- 批准号:
10538513 - 财政年份:2023
- 资助金额:
$ 34.15万 - 项目类别: